FindTrial
Sign In

Effect Of oral Iron therapy(tab.Fe(iron-200) on HbA1c(glycosylated hemoglobin) among Type 2 diabetes mellitus having iron deficiency anemia at tertiary care center

Effect Of oral Iron therapy on HbA1c among Type 2 diabetes mellitus having iron deficiency anemia tertiary care center

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/04/052130
Enrollment
300
Registered
2023-04-28
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E11- Type 2 diabetes mellitus

Interventions

Intervention1: tab.Fe(200)oral iron tablet: twice a day after food (lunch and dinner) for 3 months (90days) Control Intervention1: no oral iron supplementation (control): nil 3months(90days)

Sponsors

Government Medical college and Sir T hospital Bhavnagar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed case of T2DM having IDA attending Medicine OPD and admitted in Medicine wards.

Exclusion criteria

Exclusion criteria: (1)Severe anemia (Hb (2)Non ambulatory patients (3)Active gastrointestinal bleeding (on medical record) (4)Anemia secondary to hemolysis (on medical record) (5)Patients with allergy to iron supplements (on history) (6)Already taking iron therapy and have no recovery (on medical record) (7)Pregnancy and Lactation. (8)Patient with chronic renal failure/liver disease. (9)Malignancy

Design outcomes

Primary

MeasureTime frame
TREATING IDA IN DIABETIC PATIENTS RESULTS IN SIGNIFICANT REDUCTION OF HBA1C LEVEL.Timepoint: Outcome will be assessed/estimated at baseline and 12 weeks—

Secondary

MeasureTime frame
patient betterTimepoint: 3 months—

Countries

India

Contacts

Public ContactDr Jigneshkumar Bharatbhai Patel

government medical college bhavnagar

lakhani_krishna@yahoo.co.in919429707472

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026